NMTRQ — 9 Meters Biopharma Share News
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
Brief: 9 Meters Biopharma Announces Interim Analysis Of Phase 3 Study Of Larazotide For Celiac Disease Does Not Support Trial Continuation
Brief: 9 Meters Biopharma Q1 Loss Per Share $0.04
Brief: 9 Meters Biopharma Q4 Loss Per Share $0.04
Brief: 9 Meters Biopharma Inc Provides Clinical Update On Late-Stage Pipeline Products Vurolenatide For Short Bowel Syndrome And Larazotide For Celiac Disease
Brief: 9 Meters Biopharma Announces Allowance Of Patent For NM-102 In Combination With Immune Checkpoint Inhibitors
Brief: 9 Meters Biopharma Inc - Appoints Bethany Sensenig As CFO
Brief: 9 Meters Biopharma Qtrly Loss Per Share $0.05
Brief: 9 Meters Biopharma Inc Announces Immuno-Oncology Collaboration With Gustave Roussy For NM-102
9 Meters Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: 9 Meters Biopharma Reports Q2 Loss Per Share Of $0.03
Brief: 9 Meters Biopharma Announces Acquisition Of Humanized Anti-GIP Monoclonal Antibody From Lobesity
Brief: 9 Meters Biopharma Inc - Announces Initiation Of Phase 2 Vibrant Study Of Vurolenatide For Short Bowel Syndrome
Brief: 9 Meters Biopharma Receives Usan Approval To Use Designated Nonproprietary Name Vurolenatide For Long-Acting Glp-1 Agonist For Short Bowel Syndrome
9 Meters Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: 9 Meters Biopharma Collaborates With The Duke Clinical Research Institute
Brief: 9 Meters Biopharma Collaborates With Celiac Disease Foundation To Support Clinical Trial Enrollment In Phase 3 Trial Of Larazotide In Celiac Disease
Brief: 9 Meters Biopharma Inc Files For Offering Of 30 Million Shares Of Common Stock
U.S. STOCKS ON THE MOVE-Chewy, VirTra, Blackberry, Humanigen
9 Meters Biopharma drops on stock offering